Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy

Jay Chhablani, Francesco Pichi, Rufino Silva, Antonio Marcelo Casella, Hemanth Murthy, Alay Banker, Sawsan R. Nowilaty, Paola Carrai, Paolo Nucci, J. Fernando Arevalo

Research output: Contribution to journalArticle

Abstract

Background/Purpose: To report characteristics and treatment outcome of choroidal neovascularization (CNV) secondary to laser photocoagulation and photodynamic therapy (PDT) in central serous chorioretinopathy. Methods: Retrospective analysis of 12 eyes of 12 patients, who were diagnosed to have CNV secondary to laser photocoagulation or PDT for central serous chorioretinopathy. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation, and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last follow-up. Secondary outcomes included change in visual acuity at final follow-up from baseline, number of injections, treatment-free interval, and adverse events. Results: This study included 12 eyes of CNV secondary to laser photocoagulation (8 eyes) and PDT (4 eyes). Mean age of study subjects was 47.6 ± 15.4 years (range 33-82) with 8 men and 4 women. Mean interval between laser photocoagulation/PDT and diagnosis of CNV was 23.9 ± 54.5 months. All subjects had unilateral CNV with classic CNV on fluorescein angiography. Eight eyes had extrafoveal CNV, and four eyes had juxtafoveal CNV. Baseline best-corrected visual acuity was 0.56 ± 0.51 (Snellen equivalent 20/60) logMAR, and final best-corrected visual acuity was 0.53 ± 0.51 (Snellen equivalent 20/60) logMAR with no significant difference (P 0.84). All four eyes that presented with the CNV secondary to PDT group required additional PDT treatment because of poor response to antivascular endothelial growth factor therapy. At the last follow-up, only one patient in the laser group had active CNV; the remaining patients of both groups had scarred CNV. Mean follow-up duration was 22.4 ± 23.1 months. Mean number of injections was 3.16 ± 2.62. Longest treatment-free interval was 8.29 ± 11.4 months. Conclusion: Antivascular endothelial growth factor therapy appears to be safe and efficacious in CNVs secondary to laser photocoagulation and PDT. Choroidal neovascularizations secondary to PDT appear to be more resistant to antivascular endothelial growth factor therapy than those because of laser photocoagulation and required additional PDT.

Original languageEnglish
Pages (from-to)901-908
Number of pages8
JournalRetina
Volume36
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Central Serous Chorioretinopathy
Choroidal Neovascularization
Lasers
Photochemotherapy
Light Coagulation
Endothelial Growth Factors
Visual Acuity
Laser Therapy
Therapeutics
Injections
Fluorescein Angiography

Keywords

  • antivascular endothelial growth factor
  • central serous chorioretinopathy
  • choroidal neovascularization
  • CNV
  • CSCR

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Chhablani, J., Pichi, F., Silva, R., Casella, A. M., Murthy, H., Banker, A., ... Arevalo, J. F. (2016). Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy. Retina, 36(5), 901-908. https://doi.org/10.1097/IAE.0000000000000804

Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy. / Chhablani, Jay; Pichi, Francesco; Silva, Rufino; Casella, Antonio Marcelo; Murthy, Hemanth; Banker, Alay; Nowilaty, Sawsan R.; Carrai, Paola; Nucci, Paolo; Arevalo, J. Fernando.

In: Retina, Vol. 36, No. 5, 01.05.2016, p. 901-908.

Research output: Contribution to journalArticle

Chhablani, J, Pichi, F, Silva, R, Casella, AM, Murthy, H, Banker, A, Nowilaty, SR, Carrai, P, Nucci, P & Arevalo, JF 2016, 'Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy', Retina, vol. 36, no. 5, pp. 901-908. https://doi.org/10.1097/IAE.0000000000000804
Chhablani, Jay ; Pichi, Francesco ; Silva, Rufino ; Casella, Antonio Marcelo ; Murthy, Hemanth ; Banker, Alay ; Nowilaty, Sawsan R. ; Carrai, Paola ; Nucci, Paolo ; Arevalo, J. Fernando. / Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy. In: Retina. 2016 ; Vol. 36, No. 5. pp. 901-908.
@article{01b2f6402ab94e3898a33c28a56b6e9d,
title = "Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy",
abstract = "Background/Purpose: To report characteristics and treatment outcome of choroidal neovascularization (CNV) secondary to laser photocoagulation and photodynamic therapy (PDT) in central serous chorioretinopathy. Methods: Retrospective analysis of 12 eyes of 12 patients, who were diagnosed to have CNV secondary to laser photocoagulation or PDT for central serous chorioretinopathy. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation, and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last follow-up. Secondary outcomes included change in visual acuity at final follow-up from baseline, number of injections, treatment-free interval, and adverse events. Results: This study included 12 eyes of CNV secondary to laser photocoagulation (8 eyes) and PDT (4 eyes). Mean age of study subjects was 47.6 ± 15.4 years (range 33-82) with 8 men and 4 women. Mean interval between laser photocoagulation/PDT and diagnosis of CNV was 23.9 ± 54.5 months. All subjects had unilateral CNV with classic CNV on fluorescein angiography. Eight eyes had extrafoveal CNV, and four eyes had juxtafoveal CNV. Baseline best-corrected visual acuity was 0.56 ± 0.51 (Snellen equivalent 20/60) logMAR, and final best-corrected visual acuity was 0.53 ± 0.51 (Snellen equivalent 20/60) logMAR with no significant difference (P 0.84). All four eyes that presented with the CNV secondary to PDT group required additional PDT treatment because of poor response to antivascular endothelial growth factor therapy. At the last follow-up, only one patient in the laser group had active CNV; the remaining patients of both groups had scarred CNV. Mean follow-up duration was 22.4 ± 23.1 months. Mean number of injections was 3.16 ± 2.62. Longest treatment-free interval was 8.29 ± 11.4 months. Conclusion: Antivascular endothelial growth factor therapy appears to be safe and efficacious in CNVs secondary to laser photocoagulation and PDT. Choroidal neovascularizations secondary to PDT appear to be more resistant to antivascular endothelial growth factor therapy than those because of laser photocoagulation and required additional PDT.",
keywords = "antivascular endothelial growth factor, central serous chorioretinopathy, choroidal neovascularization, CNV, CSCR",
author = "Jay Chhablani and Francesco Pichi and Rufino Silva and Casella, {Antonio Marcelo} and Hemanth Murthy and Alay Banker and Nowilaty, {Sawsan R.} and Paola Carrai and Paolo Nucci and Arevalo, {J. Fernando}",
year = "2016",
month = "5",
day = "1",
doi = "10.1097/IAE.0000000000000804",
language = "English",
volume = "36",
pages = "901--908",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Antiangiogenics in Choroidal Neovascularization associated with laser in central serous Chorioretinopathy

AU - Chhablani, Jay

AU - Pichi, Francesco

AU - Silva, Rufino

AU - Casella, Antonio Marcelo

AU - Murthy, Hemanth

AU - Banker, Alay

AU - Nowilaty, Sawsan R.

AU - Carrai, Paola

AU - Nucci, Paolo

AU - Arevalo, J. Fernando

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background/Purpose: To report characteristics and treatment outcome of choroidal neovascularization (CNV) secondary to laser photocoagulation and photodynamic therapy (PDT) in central serous chorioretinopathy. Methods: Retrospective analysis of 12 eyes of 12 patients, who were diagnosed to have CNV secondary to laser photocoagulation or PDT for central serous chorioretinopathy. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation, and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last follow-up. Secondary outcomes included change in visual acuity at final follow-up from baseline, number of injections, treatment-free interval, and adverse events. Results: This study included 12 eyes of CNV secondary to laser photocoagulation (8 eyes) and PDT (4 eyes). Mean age of study subjects was 47.6 ± 15.4 years (range 33-82) with 8 men and 4 women. Mean interval between laser photocoagulation/PDT and diagnosis of CNV was 23.9 ± 54.5 months. All subjects had unilateral CNV with classic CNV on fluorescein angiography. Eight eyes had extrafoveal CNV, and four eyes had juxtafoveal CNV. Baseline best-corrected visual acuity was 0.56 ± 0.51 (Snellen equivalent 20/60) logMAR, and final best-corrected visual acuity was 0.53 ± 0.51 (Snellen equivalent 20/60) logMAR with no significant difference (P 0.84). All four eyes that presented with the CNV secondary to PDT group required additional PDT treatment because of poor response to antivascular endothelial growth factor therapy. At the last follow-up, only one patient in the laser group had active CNV; the remaining patients of both groups had scarred CNV. Mean follow-up duration was 22.4 ± 23.1 months. Mean number of injections was 3.16 ± 2.62. Longest treatment-free interval was 8.29 ± 11.4 months. Conclusion: Antivascular endothelial growth factor therapy appears to be safe and efficacious in CNVs secondary to laser photocoagulation and PDT. Choroidal neovascularizations secondary to PDT appear to be more resistant to antivascular endothelial growth factor therapy than those because of laser photocoagulation and required additional PDT.

AB - Background/Purpose: To report characteristics and treatment outcome of choroidal neovascularization (CNV) secondary to laser photocoagulation and photodynamic therapy (PDT) in central serous chorioretinopathy. Methods: Retrospective analysis of 12 eyes of 12 patients, who were diagnosed to have CNV secondary to laser photocoagulation or PDT for central serous chorioretinopathy. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation, and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last follow-up. Secondary outcomes included change in visual acuity at final follow-up from baseline, number of injections, treatment-free interval, and adverse events. Results: This study included 12 eyes of CNV secondary to laser photocoagulation (8 eyes) and PDT (4 eyes). Mean age of study subjects was 47.6 ± 15.4 years (range 33-82) with 8 men and 4 women. Mean interval between laser photocoagulation/PDT and diagnosis of CNV was 23.9 ± 54.5 months. All subjects had unilateral CNV with classic CNV on fluorescein angiography. Eight eyes had extrafoveal CNV, and four eyes had juxtafoveal CNV. Baseline best-corrected visual acuity was 0.56 ± 0.51 (Snellen equivalent 20/60) logMAR, and final best-corrected visual acuity was 0.53 ± 0.51 (Snellen equivalent 20/60) logMAR with no significant difference (P 0.84). All four eyes that presented with the CNV secondary to PDT group required additional PDT treatment because of poor response to antivascular endothelial growth factor therapy. At the last follow-up, only one patient in the laser group had active CNV; the remaining patients of both groups had scarred CNV. Mean follow-up duration was 22.4 ± 23.1 months. Mean number of injections was 3.16 ± 2.62. Longest treatment-free interval was 8.29 ± 11.4 months. Conclusion: Antivascular endothelial growth factor therapy appears to be safe and efficacious in CNVs secondary to laser photocoagulation and PDT. Choroidal neovascularizations secondary to PDT appear to be more resistant to antivascular endothelial growth factor therapy than those because of laser photocoagulation and required additional PDT.

KW - antivascular endothelial growth factor

KW - central serous chorioretinopathy

KW - choroidal neovascularization

KW - CNV

KW - CSCR

UR - http://www.scopus.com/inward/record.url?scp=84966642503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966642503&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000804

DO - 10.1097/IAE.0000000000000804

M3 - Article

AN - SCOPUS:84966642503

VL - 36

SP - 901

EP - 908

JO - Retina

JF - Retina

SN - 0275-004X

IS - 5

ER -